Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting

More than two-thirds of patients with breast cancer present with hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative disease at their initial diagnosis. HR-positive breast cancer’s growth depends on Cyclin D1, a direct transcriptional target of estrogen receptors...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Razeq, Hikmat, Sharaf, Baha’
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935948/
https://www.ncbi.nlm.nih.gov/pubmed/35321498
http://dx.doi.org/10.2147/DDDT.S356757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935948/
https://www.ncbi.nlm.nih.gov/pubmed/35321498
http://dx.doi.org/10.2147/DDDT.S356757

Ejemplares similares